Recombinant Rat CD155/PVR Fc Chimera Protein, CF

When Recombinant Mouse CD96 (Catalog # 5690‑CD) is coated at 1 μg/mL, 100 μL/well, Recombinant Rat CD155/PVR FcChimera (Catalog # 9744‑CD) binds with an ED50 of 1‑8 ng/mL.

• Reactivity: Rt
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Rat CD155/PVR Fc Chimera Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Mouse CD96 (Catalog # 5690-CD) is coated at 1 μg/mL (100 μL/well), the concentration of Recombinant Rat CD155/PVR Fc Chimera that produces 50% optimal binding response is 1-8 ng/mL.
• Source: Human embryonic kidney cell, HEK293-derived rat CD155/PVR protein
  

  Rat CD155/PVR (Glu34-Leu351) Accession # NP_058772	IEGRMDP	Mouse IgG2a (Glu98-Lys330)
  N-terminus		C-terminus

• Accession #: NP_058772
• N-terminal Sequence: Glu34
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 61 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 92-108 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 500 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Rat CD155/PVR Fc Chimera Protein, CF

• CD155 antigen
• CD155
• HVED
• NECL5
• Necl-5
• nectin-like 5
• Nectin-like protein 5
• poliovirus receptor
• PVR
• PVS
• PVSFLJ25946
• Tage4

Background

CD155, also known as PVR (poliovirus receptor), Necl-5 (nectin-like molecule-5) and, in rodents, TAGE4 (tumor-associated glycoprotein E4), is a 70-kDa type I transmembrane glycoprotein in the nectin-related family of adhesion proteins within the immunoglobulin superfamily (1, 2). CD155 may play a role in cancer cell invasion and migration, and binds other molecules including Vitronectin, Nectin-3, DNAM-1/CD226, CD96, and TIGIT but does not bind homophilicly (3, 4). Mature rat CD155 consists of three Ig-like domains and a 21 amino acid (aa) transmembrane segment. Within the ECD, rat CD155 shares 44% and 73% aa sequence identity with human and mouse CD155, respectively. CD155 is up-regulated on endothelial cells by IFN-gamma and is highly expressed on immature thymocytes, lymph node dendritic cells, and tumor cells of epithelial and neuronal origin (1, 2, 5-8). It is preferentially expressed on Th17 cells compared to Th2 cells (9), and its activation promotes the development of Th1 responses (10). On migrating cells, CD155 is concentrated at the leading edge, where it binds basement membrane Vitronectin, recruits Nectin-3-expressing cells, and cooperates with PDGF and Integrin alpha v beta 3 to promote cell migration (1, 3, 11). Enhanced CD155 expression in tumor cells contributes to loss of contact inhibition and increased migration but also allows tumor cell recognition and killing by DNAM-1 or CD96 expressing NK cells (1, 6, 12). Binding of monocyte DNAM-1 to endothelial cell CD155 promotes transendothelial migration (7).

1. Mandai, K. et al. (2015) Curr. Top. Dev. Biol. 112:197.
2. Ravens, I. et al. (2003) Biochem. Biophys. Res. Commun. 312:1364.
3. Sloan, K. et al. (2004) BMC Cancer. 4:73.
4. Sato, T. et al. (2004) Genes to Cells 9:791.
5. Escalante, N.K. et al. (2011) Arterioscler. Thromb. Vasc. Biol. 31:1177.
6. Xu, Z. and B. Jin (2010) Cell. Mol. Immunol. 7:11.
7. Reymond, N. et al. (2004) J. Exp. Med. 199:1331.
8. Maier, M.K. et al. (2007) Eur. J. Immunol. 37:2214.
9. Lozano, E. et al. (2013) J. Immunol. 191:3673.
10. Yamashita-Kanemaru, Y. et al. (2015) J. Immunol. 194:5644.
11. Mueller, S. and E. Wimmer (2003) J. Biol. Chem. 278:31251.
12. Chan, C.J. et al. (2010) J. Immunol. 184:902.

Bioinformatics

• Uniprot:
  • NP_058772()